Abstract

Mucin 5AC (MUC5AC) is a secreted gel-forming mucin expressed by several epithelia. In the colon, MUC5AC is expressed in scattered normal epithelial cells but can be abundant in colorectal cancers. To clarify the relationship of MUC5AC expression with parameters of tumor aggressiveness and mismatch repair deficiency (dMMR) in colorectal cancer, a tissue microarray containing 1812 colorectal cancers was analyzed by immunohistochemistry. MUC5AC expression was found in 261 (15.7%) of 1,667 analyzable colorectal cancers. MUC5AC expression strongly depended on the tumor location and gradually decreased from proximal (27.4% of cecum cancers) to distal (10.6% of rectal cancers; p < 0.0001). MUC5AC expression was also strongly linked to dMMR. dMMR was found in 21.3% of 169 cancers with MUC5AC positivity but in only 4.6% of 1051 cancers without detectable MUC5AC expression (p < 0.0001). A multivariate analysis showed that dMMR status and tumor localization predicted MUC5AC expression independently (p < 0.0001 each). MUC5AC expression was unrelated to pT and pN status. This also applied to the subgroups of 1136 proficient MMR (pMMR) and of 84 dMMR cancers. The results of our study show a strong association of MUC5AC expression with proximal and dMMR colorectal cancers. However, MUC5AC expression is unrelated to colon cancer aggressiveness.

Highlights

  • Colorectal cancer was the third most common cancer worldwide in 2018 and the second most common cause for cancer related death [1]

  • Mucin 5AC (MUC5AC) expression was significantly associated with dMMR. dMMR was found in 21.3% of 169 cancers with MUC5AC positivity but in only 4.6% of 1051 cancers without detectable MUC5AC expression (p < 0.0001, Table 2)

  • This association was independent of the tumor localization, as the frequency of dMMR cancers is higher in proximal and distal colorectal tumors with MUC5AC positive in comparison with MUC5AC-negative cancers

Read more

Summary

Introduction

Colorectal cancer was the third most common cancer worldwide in 2018 and the second most common cause for cancer related death [1]. Standard treatment of colorectal cancer consists of surgical removal. In high-risk cancers, adjuvant chemotherapy is given in order to destroy micrometastasis and to reduce the risk of local recurrence.

Material and methods
Results
Discussion
Ethical approval
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call